Results: ILK expression was detected in the endothelial cell layer of nonatherosclerotic vessels but was absent from the endothelium of atherosclerotic arteries. Live ultrasound imaging revealed that acetylcholine-mediated vasodilatation was impaired in cKO mice. These mice exhibited lowered agonist-induced nitric oxide synthase (NOS) activity and decreased cyclic guanosine monophosphate and nitrite production. ILK deletion caused endothelial NOS (eNOS) uncoupling, reflected in reduced tetrahydrobiopterin (BH4) levels, increased BH2 levels, decreased dihydrofolate reductase expression, and increased eNOS-dependent generation of superoxide accompanied by extensive vascular protein nitration. ILK reexpression prevented eNOS uncoupling in cKO cells, whereas superoxide formation was unaffected by ILK depletion in eNOS-KO cells, indicating eNOS as a primary source of superoxide anion. eNOS and ILK coimmunoprecipitated in aortic lysates from control animals, and eNOS-ILK-shock protein 90 interaction was detected in human normal mammary arteries but was absent from human atherosclerotic carotid arteries. eNOS-ILK interaction in endothelial cells was prevented by geldanamycin, suggesting heat shock protein 90 as a binding partner. Key Words: atherosclerosis Ⅲ oxidative stress Ⅲ uncoupling protein E ndothelial dysfunction is defined as impaired endothelium-dependent relaxation of blood vessels in response to the endogenous vasodilator nitric oxide (NO). Endothelial dysfunction is concomitant with changes in vascular structure associated with many forms of vascular disease, such as hypertension and atherosclerosis. 1 Atherosclerotic lesions develop mostly in areas exposed to disturbed blood flow, whereas endothelial cells exposed to laminar flow are protected against inflammatory activation and show higher relative expression of endothelial NO synthase (eNOS) and superoxide dismutase. 2, 3 Most NO in the vasculature is produced by eNOS, with a minor contribution from neuronal-type nNOS expressed in vascular smooth muscle cells. Under inflammatory conditions, vascular cells can express iNOS, which produces large amounts of NO and contributes further to vascular damage. 4 eNOS can be activated by hemodynamic forces, autacoids, hormones, and growth factors. NO relaxes vessels via activation of soluble guanylyl cyclase (sGC). The resulting elevated levels of cyclic guanosine monophosphate (cGMP) activate cGMP-dependent protein kinase type I (cGKI), which phosphorylates downstream targets that regulate the Original
ndothelial dysfunction is defined as impaired endothelium-dependent relaxation of blood vessels in response to the endogenous vasodilator nitric oxide (NO). Endothelial dysfunction is concomitant with changes in vascular structure associated with many forms of vascular disease, such as hypertension and atherosclerosis. 1 Atherosclerotic lesions develop mostly in areas exposed to disturbed blood flow, whereas endothelial cells exposed to laminar flow are protected against inflammatory activation and show higher relative expression of endothelial NO synthase (eNOS) and superoxide dismutase. 2, 3 Most NO in the vasculature is produced by eNOS, with a minor contribution from neuronal-type nNOS expressed in vascular smooth muscle cells. Under inflammatory conditions, vascular cells can express iNOS, which produces large amounts of NO and contributes further to vascular damage. 4 eNOS can be activated by hemodynamic forces, autacoids, hormones, and growth factors. NO relaxes vessels via activation of soluble guanylyl cyclase (sGC). The resulting elevated levels of cyclic guanosine monophosphate (cGMP) activate cGMP-dependent protein kinase type I (cGKI), which phosphorylates downstream targets that regulate the actin-myosin cytoskeleton and the calcium clearing mechanism, leading to vasorelaxation. 5 Many endothelial cell molecules, including integrins, sense shear stress. 6, 7 Integrin-linked kinase (ILK), a key regulator of blood vessel integrity, is a phosphoinositide 3-kinasedependent serine/threonine kinase that binds to the cytoplasmic domain of ß-integrin and lies upstream of many intracellular signaling pathways. 8, 9 ILK plays pivotal roles in angiogenesis, matrix-endothelial cell interactions, endothelial and extracellular matrix -mediated signaling, cell survival, and the recruitment of endothelial progenitors. 10 Transgenic mouse models demonstrate important roles for ILK in vascular development, 11, 12 tumor angiogenesis, 13 and cardiac hypertrophy. 14 -18 Downregulation of ILK after arterial injury correlates with neointima formation and vascular repair, 19 -22 and ILK is also implicated in the downregulation of eNOS in human endothelial cells after long-term culture in collagen type I. 23 ILK-mediated regulation of vascular function in shear stress-related vascular diseases such as atherosclerosis has not been studied previously. We investigated the vascular effects of ILK by analyzing vascular reactivity to eNOS agonists, NO/cGMP pathway activity, vascular superoxide generation, and tetrahydrobiopterin (BH4)-mediated eNOS coupling in conditionally ILK-deficient (cKO-ILK) mice and in human and mouse atherosclerotic arteries. We show that ILK stabilizes association of eNOS with heat shock protein (Hsp)90 in vivo, thereby ensuring coupling of eNOS activity to physiological production of NO rather than oxidative derivatives. This association is disrupted in atherosclerosis, suggesting ILK as a therapeutic target.
Methods
An expanded Methods section is available in the Data Supplement at http://circres.ahajournals.org.
Human Arterial Specimens
Human carotid endoarterectomy specimens were obtained from 25 patients (21 men: mean age, 75Ϯ5 years; 4 women: mean age, 71Ϯ8 years) with Ͼ70% carotid stenosis as demonstrated by digital subtraction angiography and Doppler ultrasonography. Nonatherosclerotic internal mammary artery specimens (controls) were obtained from 10 male patients (mean age, 65Ϯ5 years) undergoing coronary artery bypass surgery. All samples were obtained as surgical residues in accordance with local ethics committee regulations.
Conditional ILK Knockout Mice
Conditional inactivation of the ILK gene was accomplished by crossing mice carrying the floxed ILK allele (genotype: ILK fl/fl ) 24 with CreER T transgenic mice, which express Cre under the control of the cytomegalovirus promoter. 25 Eight-week-old male mice were injected intraperitoneally with 1.5 mg tamoxifen (dissolved in a 10:1 volumetric mix of sunflower seed oil and ethanol) once a day for 5 consecutive days. Animals were killed 20 days after the last injection. Ultrasound images were captured 3-5 days before euthanasia. In selected experiments, L-NAME (intravenous; 10 Ϫ5 mol/L per day for 4 days) was administered before ultrasound recordings. A total of 50 animals were used. All animal procedures were approved by the institutional animal care and use committee.
Results

Endothelial ILK Is Downregulated in Atherosclerotic Human and Mouse Arteries
ILK expression levels and distribution were determined by immunohistochemistry in cross sections of endarterectomy specimens of human carotid arteries (nϭ25) showing varying degrees of atherosclerosis and in mammary arteries obtained from patients undergoing coronary bypass surgery (controls) (nϭ10).
Mammary arteries, with no sign of atherosclerosis by Masson trichrome staining, showed ILK expression in the adventitia, homogeneous staining for ILK in the media, and strong staining in the endothelial layer ( Figure 1A , panel a). Intimal ILK expression was lower in endarterectomy specimens from carotid arteries showing moderate restenosis but no atherosclerotic plaque ( Figure 1A, panel b) . In atherosclerotic endarterectomy specimens, ILK staining was absent from the intima and was limited to dispersed foci in the primary plaque, whereas staining was dense and homogeneous in the restenotic regions ( Figure 1A , panel c). Thus, ILK shows a radically different distribution in atherosclerotic arteries compared with nondiseased tissue, the most significant change being its disappearance from the endothelial cell layer as atherosclerosis progresses. The integrity of the endothelial layer was confirmed by eNOS staining. Despite these changes, Western blot analysis revealed only a small and nonsignificant decrease in total ILK expression in atherosclerotic carotid arteries ( Figure 1B) .
En face confocal immunostaining of mouse aorta revealed reduced ILK staining in the endothelium of atherosclerotic ApoE KO mice compared with wild-type (WT) mice, and ILK expression was also reduced in ApoE KO mouse aortic endothelial cells (MAEC) (Figure 1C and 1D ).
ILK Regulates Vascular Reactivity In Vivo
To examine the role of ILK in endothelial function, we generated a tamoxifen-inducible ILK-deficient mice. Cre recombinase was activated in Cre ϩ /ILK fl/fl (ILK Cre-Lox) mice by injection with 4-hydroxytamoxifen (TXF). Crerecombinase-mediated excision of the Lox-P site from the floxed ILK gene in TXF-treated ILK Cre-Lox mice (cKO) was confirmed by PCR. Excision was not observed in vehicle-treated ILK Cre-Lox animals (CT) or TXF-treated Cre Ϫ /ILK fl/fl (Lox) mice (Online Figure I ). Efficient deletion of ILK after TXF administration was also observed by Western blot and immunohistochemical analysis of the aortic wall of cKO mice (Figure 2A and 2B Figure I) . Moreover, expression levels of the vascular smooth muscle marker ␣-SMA and the endothelial cell marker PECAM-1 were similar in CT and cKO mice, indicating that ILK deletion had no significant effect on vascular wall structure (Online Figure I ).
To test endothelium-dependent vasorelaxation, CT and cKO ILK Cre-Lox mice were sequentially injected with 10 Ϫ10 and 10 Ϫ8 mol/L acetylcholine (Ach), and vessel-wall diameter and Doppler blood flow in the left carotid artery were measured by high-resolution ultrasound imaging (35 MHz) . Ach caused dose-dependent vasodilatation of the carotid artery in CT mice but had no significant vasodilator effect in cKO animals ( Figure 2C ). CT and cKO animals both responded strongly to intravenous administration of 10 Ϫ7 mol/L sodium nitroprusside, indicating that NO signaling remained functional and that the loss of the Ach-induced vasodilatory response in ILK-deleted animals might reflect impaired NO production. The vasodilatory action of Ach in CT mice was accompanied by increased mean carotid Doppler blood flow, whereas this increase was not seen in cKO mice, suggesting a direct effect of ILK on the vasodilatory action of Ach ( Figure 2D ).
We next analyzed the contribution of relaxing factors (NO, prostacyclin, and endothelium-derived hyperpolarizating factor [EDHF]) on Ach-mediated vascular responses in CT mice. Mice were preteated with L-NAME (10 Ϫ5 mol/L) to inhibit NO synthesis or indomethacin (10 Ϫ5 mol/L) to inhibit prostaglandin synthesis or both drugs 30 minutes before Ach ( Figure 2E ). L-NAME reduced vessel diameter compared with saline. Subsequent administration of 10 Ϫ8 mol/L Ach did not produce an increase in diameter comparable with saline-injected mice (27Ϯ7% versus 81Ϯ10%). Indomethacin pretreatment had a limited inhibitory effect on Achinduced dilation, whereas L-NAME and indomethacin coadministration almost completely blocked Ach effect. These findings show that the response of the mouse carotid artery to Ach depends largely on NO production. EDHF does not play a relevant role in Ach effects, since L-NAME plus indomethacin inhibited the Ach response by 85Ϯ4%.
Activity of the NO/cGMP Pathway Is Reduced in Vessels and Endothelial Cells of cKO Cre-Lox Mice
We first analyzed NOS isoform expression in ILK-CT and cKO mice, finding no significant differences for eNOS ( Figure 3A and Online Figure II ) or nNOS and iNOS (Online Figure II) . However, isolated aortic rings from cKO animals failed to produce cGMP in response to Ach ( Figure 3B ), whereas treatment with the NO donor sodium nitroprusside increased cGMP production 11.8Ϯ1.2-fold, confirming that the sGC pathway is functional in cKO mice.
In further experiments, MAEC cultured from ILK Cre-Lox mice were treated with vehicle (CT MAEC, expressing ILK) or TXF to delete ILK (cKO MAEC). Treatment with the eNOS agonists calcium ionophore (A23187) and vascular endothelial growth factor (VEGF) induced accumulation of nitrite in the supernatants of CT MAEC, but this was Ϫ5 mol/L L-NAME, 10
Ϫ5 mol/L indomethacin (INDO), or both drugs, and 30 minutes after they were injected with 10 Ϫ8 mol/L Ach. Arterial diameter was measured by high-frequency ultrasound at t0 (white bars) and 2 minutes (gray bars) (nϭ10, meanϮSD; *PϽ0.05 versus t0; **PϽ0.05 versus saline t2).
abolished in cKO MAEC ( Figure 3C ). To examine the effect of ILK deletion on eNOS activity, we compared conversion of L-arginine with L-citrulline in Ach-treated CT and cKO MAEC ( Figure 3D ). Although eNOS expression was similar in both cell populations, NO production was significantly lower in cKO cells. This lower NO production was paralleled by enhanced production of superoxide, detected by DHE oxidation ( Figure 3D ), suggesting that eNOS activity might be uncoupled in cKO cells.
ILK Deletion Leads to eNOS Uncoupling and Protein Nitration
Pretreatment of cells with L-NAME prevented Ach-induced DHE oxidation in both cell populations, indicating that superoxide formation was due to eNOS activity ( Figure 4A ). Neither 7-nitroindazole (inhibitor of nNOS) nor 1400W (inhibitor of iNOS) prevented superoxide formation, indicating that nNOS and iNOS are not involved in superoxide production (Online Figure II) . Uncoupled, eNOS can generate peroxynitrite, sharply increasing oxidative stress. Increased peroxynitrite production leads to protein nitration, which is associated with cardiovascular disease. 26 As a surrogate marker of peroxynitrite, we examined protein nitration on aortic sections from CT and cKO mice by confocal immunohistochemistry, using specific antinitrotyrosine antibodies. cKO animals exhibited significant protein nitration, which was reduced by treatment with L-NAME ( Figure 4B ). Moreover, cGMP-dependent PKG-1, the common effector of the cGMP pathway, was nitrated in cKO mice (Online Figure III) . eNOS activity thus appears to be at least partially uncoupled by ILK deletion, resulting in superoxide anion production and subsequent nitration of vascular proteins such as PKG-1.
Factors that contribute to eNOS uncoupling include oxidation of the critical NOS cofactor tetrahydrobiopterin (BH4) to 7,8-dihydrobiopterin (BH2), depletion of L-arginine, reduced BH4 regeneration rate and reduction in BH4 levels due to defective synthesis. 28, 27 Both the BH4/BH2 ratio and BH4 levels determine the outcome of NOS activity and are under stringent control. HPLC analysis of aortic extracts revealed that BH4 levels are decreased in ILK-cKO mice, accompanied by an increase in BH2 ( Figure 4C ), whereas the total pteridine concentration remained unchanged. WT ILK overexpression reversed this effect and restored the BH4/BH2 ratio (Online Figure III) . Inactive BH2 is reduced back to BH4 by regeneration enzymes such as dihydrofolate reductase (DHFR) to replenish cellular BH4, which is also synthesized de novo from GTP by GTP-cyclohydrolase I (GTP-CHI). GTP-CHI expression was similar in CT and cKO mice, whereas the steady-state levels of DHFR decreased in cKO MAEC, indicating that ILK deficiency decreases the rate of BH4 regeneration, thus disrupting the BH4/BH2 balance ( Figure 4D) .
To identify the source of the superoxide responsible for BH4 deficiency in ILK-deficient mice, we measured superoxide production in ILK-cKO MAEC in the presence of specific inhibitors of candidate generating systems: NADPH oxidase, a major endothelial source of superoxide (Apocynin, 10 Ϫ4 mol/L), NOS (L-NAME, 10 Ϫ4 mol/L), xanthine oxidase (Allopurynol, 10 Ϫ4 mol/L), and the mitochondrial respiratory chain (Rotenone, 10 Ϫ5 mol/L). Allopurynol and rotenone had no effect on superoxide production, whereas apocynin reduced superoxide but did not reverse the effect of ILK deficiency. In contrast, L-NAME blocked the increase in superoxide in cKO MAEC ( Figure 5A ). To confirm eNOS as the source of the increased superoxide, we siRNA-silenced ILK expression in MAEC from eNOS-deficient mice. ILK silencing increased superoxide anion production in WT but not eNOS-KO MAEC, demonstrating a primary role for eNOS in superoxide production ( Figure 5B ). Furthermore, exposure of ILK Cre-Lox MAEC to apocynin from 24 hours before the initiation of tamoxifen-induced ILK depletion did not prevent the increase in superoxide production ( Figure  5C ), whereas treatment with L-NAME under identical conditions did so.
The increased superoxide production by cKO MAEC was reversed by overexpression of WT ILK, which also led to a small but nonsignificant reduction in superoxide production in CT MAEC ( Figure 5D ). Accordingly, ILK overexpression reversed the effects of ILK depletion on NO production, as measured by DAF-2 oxidation, and restored NO release to CT levels (Online Figure III) . In addition, eNOS-KO MAEC show a significant decrease in DHFR expression, compared with WT cells. ILK silencing decreased DHFR levels in WT but not in eNOS KO MAEC, demonstrating a novel role for endothelial NO availability in regulating BH4:BH2 ratio by the salvage pathway ( Figure 5E ).
ILK Interacts With eNOS in Endothelial Cells Through Hsp90
ILK was originally identified as a Ser/Thr kinase that also acts as a scaffold protein that sustains multiprotein complexes. 28 To investigate whether ILK-mediated coupling of eNOS to NO production depends on ILK kinase activity, cKO MAEC were transfected with V5-tagged WT ILK (ILK-WT), kinase-dead ILK (ILK-kDa), or empty vector, and eNOS activity was analyzed after stimulation with calcium ionophore. ILK-WT and ILK-kDa were equally effective at restoring eNOS activity in cKO MAEC (Online Figure IV) . ILK can activate Akt, which activates eNOS via phosphorylation on Ser1177. 29 Treatment with the Akt activators VEGF or calcium ionophore increased eNOS phosphorylation in CT MAEC but not in cKO MAEC, although Akt phosphorylation is increased in cKO MAEC (Online Figure IV) . Taken together, ILK Ser/Thr kinase activity does not contribute to the effects observed on ILK depletion.
To test whether ILK interacts with eNOS by acting as a chaperone protein we used a yeast 2-hybrid strategy. Neither full-length ILK nor fragments corresponding to residues 1-150 or 155-452 showed a positive interaction with either the heme oxygenase or the reductase domain of eNOS (Online Table I ). Control experiments showed strong interaction between eNOS heme oxygenase domain monomers and between the heme oxygenase and reductase domains.
The most likely explanation of these results is that ILK associates with eNOS through a linker protein, a likely candidate being Hsp90, a binding partner of both eNOS and ILK. 30, 31 Immunoprecipitation of eNOS from aortic lysates detected coprecipitation of ILK and Hsp90 in CT mice, and the levels of both proteins in eNOS immunoprecipitates were significantly lower in cKO extracts ( Figure 6A ). Association between ILK, eNOS, and Hsp90 was confirmed by cross coimmunoprecipitation with anti-ILK and anti-eNOS antibodies in CT and cKO MAEC lysates ( Figure 6B ). Immunoblotting confirmed similar Hsp90 levels in CT and cKO mice ( Figure 6B ; input). These results suggest that ILK may serve as a scaffold protein in a complex that regulates eNOS activity in endothelial cells.
To confirm the clinical significance of these results, we examined ILK interactions in human tissue extracts. Immunoprecipitation of ILK and eNOS from extracts of human mammary and carotid artery detected interaction between ILK and eNOS in nonatherosclerotic tissue, but this interaction was absent in atherosclerotic samples ( Figure 6C ). Moreover, Hsp90 was coprecipitated with ILK or eNOS in protein extracts of healthy mammary arteries and this interaction was reduced in atherosclerotic carotid arteries.
To isolate complexes containing eNOS-interacting proteins, we passed cell lysates through Ni-NTA agarose columns loaded with 6xHis-tagged recombinant eNOS. Lysates of bovine aortic endothelial cells (BAEC), which express high levels of ILK, were added to the column and eluted proteins were detected by immunoblot. ILK and Hsp90 were eluted from the column together with eNOS in lysates of Figure 4 . ILK deletion increases superoxide production and protein nitration in intact vessels and endothelial cells. A, Superoxide produced by CT and cKO MAEC untreated (NT), treated with L-NAME (10 Ϫ4 mol/L, 18 hours), with Ach (10 Ϫ7 mol/L, 30 minutes), or AchϩL-NAME (nϭ5, meanϮSD; *PϽ0.05 versus NT CT, **PϽ0.05 versus Ach). B, Confocal detection of 3-nitrotyrosine in aortic sections from CT mice, cKO mice, and cKO mice treated with L-NAME (nϭ3, barsϭ75 m). C, HPLC analysis of the content of total biopterins, BH4 and BH2, in aortic extracts from CT and cKO mice (nϭ10, meanϮSD; *PϽ0.05 versus CT BH4; **PϽ0.05 versus CT BH2). D, Immunoblot analysis of GTP-CH-I, DHFR, ILK, and GADPH in extracts from CT and cKO MAEC. Two independent samples of each cell type are shown (nϭ5, meanϮSD; *PϽ0.05 versus CT).
untreated BAEC, but pretreatment of cells with the Hsp90 inhibitor geldanamycin significantly reduced the levels of coeluting ILK and eNOS ( Figure 7A ). Similar results were obtained when MAEC were treated with GA and subjected to ILK immunoprecipitation ( Figure 7B ).
The role of ILK in regulating eNOS-Hsp90 interaction was confirmed by overexpression of WT ILK in cKO cells, which reverted the effects of ILK deletion on the eNOS:Hsp90 ratio ( Figure 7C ). These results indicate that ILK regulates eNOS activity by stabilizing a multiprotein complex of which Hsp90 is an essential component.
Discussion
Our results identify an important role for ILK as a mediator of endothelial function. By stabilizing the association of eNOS with Hsp90 in a signaling complex, ILK protects eNOS from enzymatic uncoupling and promotes the physiological production of NO rather than oxidative derivatives, thus preventing endothelial dysfunction.
We have established a link between atherosclerosis and decreased expression of ILK in the endothelium in human atherosclerotic blood vessels and in atherosclerotic mice.
Proatherogenic stimuli such as oxidized LDL and angiotensin II regulate ILK activity and expression in cultured endothelial and vascular smooth muscle cells. 32, 33 ILK expression is also reduced in several models of arterial injury characterized by intimal thickening. 19 -22 These findings suggest a role for ILK in the progression of pathological vascular remodeling such as atherosclerosis.
In the cardiovascular system, ILK plays a role in blood vessel integrity and participates in angiogenesis and endothelial cell migration. 21, 34, 35 ILK also has a critical role in cardiac development and function, particularly as a component of the cardiac stretch sensor. 36 However, little is known about the postnatal physiological role of ILK in relation to NO synthesis and vascular function. Our use of a conditional ILK knockout (KO) model circumvents the embryonic lethality of conventional ILK KO. 37 Conditional deletion of ILK in adult mice resulted in vasomotor dysfunction as a consequence of impaired endothelial production of nitric oxide. Individual vascular beds exhibit differences in vascular reactivity. NO is generally regarded as a major contributor to endotheliumdependent relaxation in large conduit arteries, whereas EDHF may play an important role in small arteries. 38 However, our results demonstrate that the response to Ach was largely dependent on NO production and EDHF had only a small contribution. eNOS uncoupling, characterized by increased production of superoxide by eNOS and reduction of NO production, is a common feature of hypertension and atherosclerosis. Our data show that ILK deficiency leads to a shift in eNOS activity from NO production to superoxide production, suggesting eNOS uncoupling as the underlying mechanism for the observed effects. Indeed, ILK overexpression reversed eNOS uncoupling and restored eNOS enzyme activity. PKG-1, the target of cGMP, was nitrated in the absence of ILK. PKG-1 nitration has been described recently as a major contributor to pulmonary hypertension in a mouse model of chronic eNOS activation secondary to loss of caveolin-1 39 ; however, we did not find histological markers of pulmonary vessel remodeling in the CreLox model of ILK deletion. In addition, PKG-1 nitration could lead to defective vasorelaxation, since active PKG-1 phosphorylates components of the actin-myosin myofilaments and calcium metabolism, leading to vasorelaxation and contributing further to endothelial dysfunction.
BH4, a cofactor for NOS enzymes, is required for efficient NO production. The coupling of BH4 to L-arginine inhibits this production of superoxide anion, since BH 4 maintains eNOS dimerization and transfers electrons during L-arginine oxidation. 40 When BH4 availability is limiting, eNOS generates superoxide rather than NO and BH4 becomes oxidized to catalytically incompetent BH2, resulting in an imbalance in the BH4:BH2 ratio. 41 It seems that BH4:BH2 ratio is more important in determining the fate of eNOS activity than net BH4 levels. 42 In agreement with this, reduced BH4 levels, increased BH2 and reduced BH4:BH2 ratio were found in ILK cKO MAEC.
There is evidence that persisting oxidative stress would render eNOS uncoupling. In this context, NADPH oxidase, which has been suggested as a major superoxide anion source in the vasculature, can further contribute to oxidant stress not only by producing superoxide anion but also by initiating BH4 oxidation. 43, 44 However, in cKO MAEC superoxide production is inhibited by the NOS inhibitor L-NAME and it is not completely reversed by the NADPH oxidase inhibitor apocynin. Moreover, increased superoxide production in response to ILK silencing is abolished in eNOS-null mouse aortic endothelial cells. Thus, uncoupled eNOS is the primary source of superoxide in the absence of ILK. However, a contribution of NADPH oxidase cannot be excluded because a reduction in superoxide levels was observed in both CT and cKO MAEC by NADPH oxidase inhibition.
Our study is the first to indicate a role for ILK in BH4 metabolism. BH4 depletion in ILK-cKO mice might be a consequence of a direct effect on BH4 synthesis or an indirect consequence of the increased levels of oxidative radicals contributing to BH4 oxidation. Our results show that ILK deficiency does not decrease BH4 levels directly, since GTP-CHI expression remained constant in CT and cKO MAEC but rather decreased BH4 regeneration by the salvage pathway. DHFR, an enzyme that reconverts BH2 in BH4, is downregulated in ILK cKO MAEC. Under conditions of oxidative stress, as induced by angiotensin II, hypertension, or diabetes, DHFR activity or levels are decreased in endothelium, suggesting that insufficient recycling of BH2 to BH4 by DHFR is at least in part responsible for the attenuated BH4 levels, leading to eNOS uncoupling. [45] [46] [47] However, our results demonstrate that eNOS uncoupling is the primary source of superoxide in the absence of ILK. Our data strongly suggest that DHFR downregulation is a direct consequence of ILK deletion and subsequent decrease in NO production by eNOS, since ILK silencing in eNOS null MAEC did not downregulate DHFR. Thus, DHFR downregulation could contribute secondarily or in parallel to BH4/BH2 imbalance. ILK reexpression in cKO MAEC reduced superoxide production, increased NO production, and restored the BH4:BH2 ratio, supporting the idea that ILK deficiency is upstream of BH4/BH2 imbalance in eNOS uncoupling.
In search of a mechanism that explained how ILK regulated eNOS and its production of NO and superoxide, we discovered that ILK interacts with eNOS in endothelial cells, in CT mice, and in human healthy mammary arteries. This interaction is not present in human atherosclerotic arteries or ILK-deficient vessels. However, this interaction is indirect and is prevented by inhibition of Hsp90, strongly suggesting that eNOS and ILK form part of a multiprotein complex containing Hsp90. Accordingly, ILK overexpression in cKO MAEC reversed the observed defect in eNOS-Hsp90 association. Hsp90 binds to and stabilizes eNOS, promotes NO generation, and inhibits eNOS-mediated superoxide anion generation. 48, 49 ILK also interacts with Hsp90, preventing ILK degradation by the proteasome. 31, 50, 51 It may be that Hsp90 regulates interaction between eNOS and ILK, because Hsp90 can interact with other client proteins that could compete with ILK or even recruit ubiquitin ligases that could regulate protein stability of either eNOS or ILK. Our data thus suggest a role for ILK-eNOS-Hsp90 interaction in eNOS activity and indicate that disruption of this interaction might underlie the endothelial dysfunction associated with vascular diseases such as atherosclerosis.
Considering that ILK forms part of a signaling platform that transduces mechanical forces (such as shear stress) to the cell interior, the interaction of ILK with Hsp90 and eNOS provides an additional control on eNOS enzymatic activity.
